Connect Biopharma Holdings Limited (CNTB) is developing rademikibart, an antibody drug similar in action to the blockbuster Dupixent, aimed at treating asthma and chronic obstructive pulmonary disease (COPD). The company is close to releasing results from two clinical trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, which could demonstrate benefits for acute exacerbations in these conditions. CNTB raised $18.6 million in Q1 2026 through a private placement and held $46 million in cash at the end of the quarter, positioning it well for upcoming developments.
Huhtamaki's Board has introduced a new Share Ownership Plan 2026-2030 for its Global Executive Team, requiring personal investment in company shares. The plan aims to increase executive shareholding, align interests with shareholders, and support lon...
Dassault Systèmes has agreed to acquire ArisGlobal for approximately $1.8 billion in cash, with an additional potential $200 million based on AI-related revenue targets. This acquisition aims to create the first unified AI platform for life sciences,...
Nestlé and Platinum Equity have announced a 50:50 joint venture named Peranel, combining Nestlé's waters and premium beverages business. Peranel will manage over 30 brands, including S.Pellegrino, Perrier, and Acqua Panna, with products sold in 120 c...
The Rosen Law Firm is investigating a potential class action lawsuit on behalf of shareholders of America’s Car-Mart, Inc. following allegations that the company provided misleading business information. This comes after a significant stock drop of 1...
U.S. crude oil inventories rose by 2 million barrels but remain below the five-year average, supporting a bullish trend for WTI crude oil, which is trading above $88 and targeting $90.73. Strong gasoline and jet fuel demand, along with geopolitical r...
